RNAZ net incomeQ2 2026-$6.75M
RNAZ net income was -$6.75M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.28M a year earlier. For the full fiscal 2025 it was -$34.66M, compared with -$16.75M in fiscal 2024.
TransCode Therapeutics Inc. (RNAZ) financials
For the twelve months ended Jun 30, 2026, TransCode Therapeutics Inc. reported -$42.83M of net income.
- Net income, TTM
- -$42.83M
- Cash
- $8.38M
- Market cap
- $26.1M
FY2020FY2025
FY2021FY2025
RNAZ revenue and earnings growth
RNAZ EPSQ2 2026-$7.17
RNAZ diluted EPS was -$7.17 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.13 a year earlier. For the full fiscal 2025 it was -$52.59.
RNAZ free cash flowFY2025-$19.52M
RNAZ free cash flow was -$19.52M for fiscal 2025 (ended Dec 31, 2025), compared with -$13.36M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $13.42M | $9.71M | $12.26M | $10.23M | $2.75M | $284.5K |
| Selling, general and admin | $5.77M | $5.95M | $7.15M | $8.40M | $3.40M | $442.1K |
| Operating income | -$27.98M | -$15.66M | -$19.42M | -$18.63M | -$6.15M | -$726.6K |
| Interest expense | $6.6K | $26.8K | $55.9K | $32.0K | $95.1K | $394.6K |
| Pre-tax income | -$34.44M | -$16.75M | - | - | - | - |
| Income tax | $226.1K | $0 | $0 | $0 | $53.1K | $0 |
| Net income | -$34.66M | -$16.75M | -$18.55M | -$17.56M | -$6.84M | -$2.34M |
| EPS, basic | -$52.59 | -$1336.63 | -$3419.01 | -$1036230.03 | -$15503.40 | -$9761.40 |
| EPS, diluted | -$52.59 | -$1336.63 | -$3419.01 | -$1036230.03 | -$15503.40 | -$9761.40 |
| Diluted shares | 689,713 | 12,558 | 5,424 | 16.951 | 440.224 | 242.227 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $17.81M | $5.81M | $2.77M | $4.97M | $20.83M | $828.0K |
| Current assets | $21.98M | $7.09M | $4.46M | $7.38M | $22.73M | $831.2K |
| Goodwill | $25.74M | - | - | - | - | - |
| Total assets | $162.40M | $7.29M | $5.17M | $7.59M | $22.94M | $1.06M |
| Current liabilities | $3.49M | $2.77M | $3.49M | $4.35M | $2.53M | $404.9K |
| Total liabilities | $10.52M | $9.31M | $3.53M | $4.35M | $2.53M | $4.46M |
| Shareholders' equity | $10.34M | -$2.02M | $1.64M | $3.24M | $20.40M | -$3.41M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$19.52M | -$13.34M | -$18.07M | -$15.76M | -$5.27M | -$493.0K |
| Capital expenditures | $6.7K | $21.8K | $35.6K | $100.9K | $254.8K | - |
| Free cash flow | -$19.52M | -$13.36M | -$18.11M | -$15.86M | -$5.52M | - |
| Investing cash flow | -$4.4K | -$21.8K | -$35.6K | -$100.9K | -$251.8K | - |
| Financing cash flow | $31.52M | $16.40M | $15.91M | $6.0K | $25.52M | $1.12M |
| Stock-based compensation | $485.4K | $1.70M | $1.04M | $395.3K | $186.0K | $45.4K |
| Depreciation and amortization | $76.4K | $90.9K | $123.5K | $98.6K | $42.5K | $0 |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.69M | $5.11M | $5.48M | $3.16M | $2.57M | $2.22M | $3.64M | $1.23M | $3.08M | $1.76M | $3.36M | $3.34M |
| Selling, general and admin | $2.54M | $2.22M | $1.76M | $1.40M | $1.66M | $951.7K | $1.45M | $938.0K | $2.03M | $1.53M | $734.0K | $1.97M |
| Operating income | -$6.79M | -$17.76M | -$16.03M | -$4.56M | -$4.22M | -$3.17M | -$5.09M | -$2.17M | -$5.11M | -$3.29M | -$4.10M | -$5.31M |
| Interest expense | - | - | $542 | $6.0K | $0 | $114 | $1.8K | $10.8K | $4.5K | $9.7K | $17.3K | $17.3K |
| Pre-tax income | -$6.75M | -$17.55M | - | - | -$4.28M | -$12.09M | - | - | - | - | - | - |
| Income tax | - | - | $226.1K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.75M | -$17.79M | -$13.44M | -$4.86M | -$4.28M | -$12.09M | -$5.92M | -$2.32M | -$5.19M | -$3.33M | -$4.09M | -$5.30M |
| EPS, basic | -$7.17 | -$21.28 | - | -$5.82 | -$5.13 | -$70.16 | - | -$146.06 | -$680.23 | -$21.35 | - | -$1598.52 |
| EPS, diluted | -$7.17 | -$21.28 | - | -$5.82 | -$5.13 | -$70.16 | - | -$146.06 | -$680.23 | -$21.35 | - | -$1598.52 |
| Diluted shares | 957,191 | 916,968 | - | 833,683 | 833,653 | 172,262 | - | 15,893 | 7,631 | 155,831 | - | 3,315.545 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.38M | $12.84M | $17.81M | $2.84M | $7.37M | $11.57M | $5.81M | $1.88M | $3.35M | $4.91M | $2.77M | $7.45M |
| Current assets | $10.64M | $16.75M | $21.98M | $4.75M | $8.24M | $13.04M | $7.09M | $3.61M | $4.39M | $6.71M | $4.46M | $9.37M |
| Goodwill | $25.74M | $25.74M | $25.74M | - | - | - | - | - | - | - | - | - |
| Total assets | $151.01M | $157.16M | $162.40M | $5.23M | $8.27M | $13.19M | $7.29M | $3.94M | $4.82M | $7.29M | $5.17M | $10.23M |
| Current liabilities | $5.40M | $5.38M | $3.49M | $2.97M | $1.56M | $2.51M | $2.77M | $2.28M | $3.50M | $2.71M | $3.49M | $5.60M |
| Total liabilities | $12.65M | $12.64M | $10.52M | $3.80M | $2.12M | $2.90M | $9.31M | $2.28M | $3.50M | $2.71M | $3.53M | $5.79M |
| Shareholders' equity | -$27.69M | $1.25M | $10.34M | $1.43M | $6.15M | $10.29M | -$2.02M | $1.65M | $1.32M | $4.58M | $1.64M | $4.44M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.40M | -$4.98M | -$8.14M | -$4.08M | -$4.19M | -$3.10M | -$3.15M | -$3.91M | -$2.34M | -$3.94M | -$5.66M | -$3.51M |
| Capital expenditures | - | - | - | - | - | - | $500 | $12.9K | $4.6K | $3.8K | $0 | $4.6K |
| Free cash flow | - | - | - | - | - | - | -$3.15M | -$3.93M | -$2.34M | -$3.94M | -$5.66M | -$3.51M |
| Investing cash flow | - | - | - | - | - | - | -$500 | -$12.9K | -$4.6K | -$3.8K | $0 | -$4.6K |
| Financing cash flow | - | - | $23.12M | -$455.7K | $0 | $8.85M | $7.08M | $2.45M | $785.2K | $6.09M | $978.2K | $7.39M |
| Stock-based compensation | - | - | $61.9K | $134.3K | $131.5K | $157.7K | $168.8K | $204.5K | $1.14M | $183.2K | $310.3K | $392.3K |
| Depreciation and amortization | $23.9K | $23.9K | $44.8K | $4.8K | $13.4K | $13.4K | $10.3K | $16.0K | $32.4K | $32.2K | $31.7K | $31.2K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.97 | 3.11 | 6.29 | 1.60 | 5.27 | 5.20 | 2.56 | 1.58 | 1.25 | 2.48 | 1.28 | 1.67 |
Source: XBRL data TransCode Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 14, 2023; 1-for-29, first reported Nov 14, 2024; 1-for-33, first reported Apr 15, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
RNAZ peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RNAZ | - | - | -$42.83M | - | $26.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
RNAZ FAQ
4 questionsIs RNAZ profitable?
No. TransCode Therapeutics Inc. reported a net loss of $42.83M for the twelve months ended Jun 30, 2026.How much cash and debt does RNAZ have?
TransCode Therapeutics Inc. reported $8.38M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did RNAZ last report financial results?
The latest statements here come from TransCode Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this RNAZ financial data come from?
Quantisnow builds these statements from the structured XBRL data TransCode Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.